“NMIBC is a recurrent and progressive cancer, which Theralase believes it’s TLD-1433 therapy can make a significant difference in. Current standards of care for NMIBC including BCG, chemotherapy and immunotherapy, are not curative in nature and unfortunately are associated with considerable morbidity. This underscores the urgent need for new treatment options like Theralase’s TLD-1433 PDT for patients contending with this debilitating and fatal disease.”

Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase®

“I am pleased that the clinical results of the Study met its objectives demonstrating that the Theralase PDT technology has demonstrated potential as a treatment for bladder cancer.”

Dr. Michael Jewett, MD, FRCSC, FACS, Professor of Surgery (Urology) at the University of Toronto and the Chairman of Theralase’s Medical and Scientific Advisory Board

“I believe that TLD-1433 holds real potential as a treatment for NMIBC and I look forward to treating additional patients in the pivotal Phase II NMIBC clinical study”

Dr. Girish Kulkarni, MD, PhD, FRCSC, an Associate Professor at the University of Toronto, Department of Surgery and Theralase’s Principal Investigator at University Health Network, Princess Margaret Cancer Centre

“Currently, cystectomy remains the safest treatment option available to patients, but if the Theralase PDT achieves its efficacy endpoint in a Phase II clinical study, then this will present patients with an attractive additional treatment option. The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.”

Dr. Ashish Kamat, MD, MBBS, Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research, University of Texas, MD Anderson Cancer Center, member of Theralase’s Medical and Scientific Advisory Board